Henrik Hammarén

Henrik Hammarén

Auto-generated profile, based on publicly available information

Henrik Hammarén

Structural and Computational Biology Unit, European Molecular Biology Laboratory

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2013 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
JMJames M. Murphy
James M. Murphy
QZQingwei Zhang
Qingwei Zhang
SYSamuel N. Young
Samuel N. Young
MRMichael L. Reese
Michael L. Reese
FBFiona P. Bailey
Fiona P. Bailey
ILIsabelle S. Lucet
Isabelle S. Lucet
Protein kinase-like domains that lack conserved residues known to catalyse phosphoryl transfer, termed pseudokinases, have emerged as important signalling domains across all kingdoms of life. Although predicted to function principally as catalysis-independent protein-interaction modules, several pseudokinase domains have been attributed unexpected catalytic functions, often amid controversy. We established a thermal-shift assay as a benchmark technique to define the nucleotide-binding properties of kinase-like domains. Unlike in vitro kinase assays, this assay is insensitive to the presence of minor quantities of contaminating kinases that may otherwise lead to incorrect attribution of catalytic functions to pseudokinases. We demonstrated the utility of this method by classifying 31 diverse pseudokinase domains into four groups: devoid of detectable nucleotide or cation binding; cation-independent nucleotide binding; cation binding; and nucleotide binding enhanced by cations. Whereas nine pseudokinases bound ATP in a divalent cation-dependent manner, over half of those examined did not detectably bind nucleotides, illustrating that pseudokinase domains predominantly function as non-catalytic protein-interaction modules within signalling networks and that only a small subset is potentially catalytically active. We propose that henceforth the thermal-shift assay be adopted as the standard technique for establishing the nucleotide-binding and catalytic potential of kinase-like domains.

1 June 2012 in Faraday Discussions
Verified
Journal Article
Closed access
PDF file
MJMatti Javanainen
Matti Javanainen
HHHenrik Hammaren
Henrik Hammaren
LMLuca Monticelli
Luca Monticelli
JJJae-Hyung Jeon
Jae-Hyung Jeon
MMMarkus S. Miettinen
Markus S. Miettinen
IVIlpo Vattulainen
Ilpo Vattulainen
Lateral diffusion plays a crucial role in numerous processes that take place in cell membranes, yet it is quite poorly understood in native membranes characterized by, e.g., domain formation and large concentration of proteins. In this article, we use atomistic and coarse-grained simulations to consider how packing of membranes and crowding with proteins affect the lateral dynamics of lipids and membrane proteins. We find that both packing and protein crowding have a profound effect on lateral diffusion, slowing it down. Anomalous diffusion is observed to be an inherent property in both protein-free and protein-rich membranes, and the time scales of anomalous diffusion and the exponent associated with anomalous diffusion are found to strongly depend on packing and crowding. Crowding with proteins also has a striking effect on the decay rate of dynamical correlations associated with lateral single-particle motion, as the transition from anomalous to normal diffusion is found to take place at macroscopic time scales: while in protein-poor conditions normal diffusion is typically observed in hundreds of nanoseconds, in protein-rich conditions the onset of normal diffusion is tens of microseconds, and in the most crowded systems as large as milliseconds. The computational challenge which results from these time scales is not easy to deal with, not even in coarse-grained simulations. We also briefly discuss the physical limits of protein motion. Our results suggest that protein concentration is anything but constant in the plane of cell membranes. Instead, it is strongly dependent on proteins' preference for aggregation.

1 June 2019 in Cytokine
Verified
Journal Article
Open access
HHHenrik M. Hammarén
Henrik M. Hammarén
AVAnniina T. Virtanen
Anniina T. Virtanen
JRJuuli Raivola
Juuli Raivola
OSOlli Silvennoinen
Olli Silvennoinen
The JAK-STAT signal transduction pathway is responsible for mediating signals of over fifty cytokines, growth factors and hormones. Signaling through the JAK-STAT pathway is regulated on multiple levels, including intramolecular regulation by the JAK pseudokinase domain, and intermolecular regulation by a host of regulatory proteins. The advent of accessible genomic tools have provided a wealth of information on disease-associated mutations in the JAK-STAT pathway and its regulatory components. The vast number of these mutations in diseases ranging from immunodeficiencies and obesity to many cancers highlight the importance of correct regulation of JAK-STAT signaling for biological processes such as hematopoiesis, regulation of the immune system, metabolism, and growth. Simultaneously, JAK inhibitors are gaining traction in clinical use, both for treatment of diseases driven by JAK mutations, and for a host of inflammatory disorders, in which proinflammatory cytokine signaling through the JAK-STAT pathway is an integral part of pathogenesis. The elucidation of molecular mechanisms in the pathogenesis of complex diseases has also, however, brought the limitations of our current understanding on the regulation of cytokine signaling to the foreground. Indeed, deeper understanding of these regulatory mechanisms are a prerequisite for the development of the next generation of pharmacological modulators of the JAK-STAT pathway. In this review we discuss the current state of knowledge of the intra- and intermolecular regulation of the JAK-STAT pathway, with a focus on diseases arising from disruptions in the regulatory apparatus.

14 May 2010 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
PNPerttu S. Niemelä
Perttu S. Niemelä
MMMarkus S. Miettinen
Markus S. Miettinen
LMLuca Monticelli
Luca Monticelli
HHHenrik Hammaren
Henrik Hammaren
PBPär Bjelkmar
Pär Bjelkmar
IVIlpo Vattulainen
Ilpo Vattulainen

11 June 2014 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
YSYibing Shan
Yibing Shan
KGKavitha Gnanasambandan
Kavitha Gnanasambandan
DUDaniela Ungureanu
Daniela Ungureanu
EKEric T Kim
Eric T Kim
HHHenrik Hammarén
Henrik Hammarén
SHStevan R Hubbard
Stevan R Hubbard

1 November 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
XMXiaoshan Min
Xiaoshan Min
DUDaniela Ungureanu
Daniela Ungureanu
SMSarah Maxwell
Sarah Maxwell
HHHenrik Hammarén
Henrik Hammarén
STSteve Thibault
Steve Thibault
ZWZhulun Wang
Zhulun Wang
JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) participates in signaling through cytokine receptors involved in immune responses and inflammation. JAKs are characterized by dual kinase domain: a tyrosine kinase domain (JH1) that is preceded by a pseudokinase domain (JH2). The majority of disease-associated mutations in JAKs map to JH2, demonstrating its central regulatory function. JH2s were considered catalytically inactive, but JAK2 JH2 was found to have low autoregulatory catalytic activity. Whether the other JAK JH2s share ATP binding and enzymatic activity has been unclear. Here we report the crystal structure of TYK2 JH2 in complex with adenosine 5′-O-(thiotriphosphate) (ATP-γS) and characterize its nucleotide binding by biochemical and biophysical methods. TYK2 JH2 did not show phosphotransfer activity, but it binds ATP and the nucleotide binding stabilizes the protein without inducing major conformational changes. Mutation of the JH2 ATP-binding pocket increased basal TYK2 phosphorylation and downstream signaling. The overall structural characteristics of TYK2 JH2 resemble JAK2 JH2, but distinct stabilizing molecular interactions around helix αAL in the activation loop provide a structural basis for differences in substrate access and catalytic activities among JAK family JH2s. The structural and biochemical data suggest that ATP binding is functionally important for both TYK2 and JAK2 JH2s, whereas the regulatory phosphorylation appears to be a unique property of JAK2. Finally, the co-crystal structure of TYK2 JH2 complexed with a small molecule inhibitor demonstrates that JH2 is accessible to ATP-competitive compounds, which offers novel approaches for targeting cytokine signaling as well as potential therapeutic applications.